Researchers say securing funding has become increasingly tough, with many left with no choice but to spend a disproportionate amount of time applying for grants.

Gene regulatory changes are considered major drivers of evolutionary innovations, including the cerebellum’s expansion during human evolution, yet they remain largely unexplored. In this study, we com...

what happens when AI automates "normal science"?

The existing ENCODE registry of candidate human and mouse cis-regulatory elements is expanded with the addition of new ENCODE data, integrating new functional data as well as new cell and tissue types...

Author summary One powerful way to study regulation is to examine hybrids between two inbred species, where each gene has two distinct parental copies, or alleles. Measuring how much each allele is ex...

Decoding cell identity from DNA alone is a challenge. Here, the authors demonstrate that counting transcription factor motifs in regulatory DNA can forecast cell-type specificity outperforming deep-le...

A map of DNA methylation changes in human organs could help researchers to discover more targets for anti-ageing therapies.

The Medical Research Future Fund (MRFF) was designed to deliver $1 billion each year in new, lifesaving funding for medical research. We know through financial modelling that the full amount can be re...

In these financially straitened times, funders must recognize that great discoveries often arise from work that was looking for something completely different.

Join us at the Keystone Symposia on Epigenetics and Gene Regulation in Health and Disease: Linking Basic Mechanisms with Therapeutic Opportunities, March 2026, in Geneva, with field leaders!

Competition between transcription factors and mismatch repair machinery drives localized hypermutation at regulatory elements, with implications for cancer and genome evolution.

Cell-extrinsic cues are key for neocortical cell identity and diversity.

Peter Mac is recruiting a Group Leader to increase the capacity and efficiency of our “discovery to translation” cancer research pipeline.